SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial, a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO. As part of the planned launch, Vial has established an Ophthalmology Scientific Board in order to get feedback from PIs and leaders in the field before the CRO launch. Vial is pleased to announce that Dr. Nancy Holekamp of the Pepose Vision Institute was brought on as an advisor. Dr. Holekamp joins the founding member, Dr. Arshad Khanani, on the Ophthalmology SAB.
Dr. Holekamp currently serves as the Director of Retina Services at the Pepose Vision Institute in St. Louis, MO. Prior to her role there, she was a Professor of Clinical Ophthalmology and Visual Sciences at the Washington University School of Medicine in St. Louis. Dr. Holekamp received her Medical Degree from Johns Hopkins School of Medicine Alpha Omega Alpha.
Throughout her career, Dr. Holekamp has been the principal investigator or sub-investigator for 35+ ophthalmic trials. The trials she has participated in include some of the most prevalent indications in retina, including age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy.
"The world of Ophthalmology research is constantly evolving and I believe that Vial can be a major contributor to accelerating that progress. I look forward to advising the Vial team on their Ophthalmology CRO in order to solve many of the challenges I've seen first-hand as a PI," said Dr. Holekamp on her new position.
Vial's next-generation CRO is working to reimagine clinical trials. Through a technology platform and operations playbook, Vial has built "The CRO Built for Sponsors" that promises faster execution and higher quality trial outcomes. After launching in Dermatology, the Vial CRO has worked with Ophthalmic sponsors (posterior and anterior) to refine the next-gen CRO model with strong traction in Dermatology to the nuances of Ophthalmology.
See the full release here.
About Vial: Vial's mission is to empower scientists to cure all human disease. Vial has executed on that vision by launching a next-generation CRO (live in Dermatology CRO, with slated launches in Ophthalmology CRO, Oncology CRO, Gastroenterology CRO), a site network (Dermatology Clinical Trials, Ophthalmology Clinical Trials, Gastroenterology Clinical Trials, Women's Health Clinical Trials, Neurology Clinical Trials), and technology platform (VialConnect CTMS) to accelerate research.
View original content to download multimedia:https://www.prnewswire.com/news-releases/dr-nancy-holekamp-of-the-pepose-vision-institute-joins-vial-as-an-advisor-to-their-ophthalmology-cro-301580873.html